{"generic":"Albumin, Iodinated I-131","drugs":["Albumin, Iodinated I-131","Volumex"],"mono":{"0":{"id":"925314-s-0","title":"Generic Names","mono":"Albumin, Iodinated I-131"},"1":{"id":"925314-s-1","title":"Dosing and Indications","sub":{"0":{"id":"925314-s-1-4","title":"Adult Dosing","mono":"<ul><li>Lugol's Solution (Strong Iodine Solution USP) prior to administration; begin use at least 24 hours before administration, 10 drops ORALLY three times daily; continue 1 to 2 weeks thereafter<\/li><li><b>Blood volume estimation; Diagnosis:<\/b> 0.185 to 1.85 megabecquerels (5 to 50 microcuries) IV; MAX 200 microcuries weekly for repeated dosing; premedicate with Lugol's solution 10 drops ORALLY three times daily starting at least 24 hours before administration, continue 1 to 2 weeks<\/li><li><b>Isotope study of blood volume, Determination of cardiac and pulmonary blood volume; Diagnosis:<\/b> 75 to 130 microcuries IV; MAX 7.4 megabecquerels (200 microcuries) weekly for repeated dosing; premedicate with Lugol's solution 10 drops ORALLY three times daily starting at least 24 hours before administration, continue 1 to 2 weeks<\/li><li><b>Measurement of cardiac output; Diagnosis:<\/b> 3 to 50 microcuries IV; MAX 200 microcuries weekly for repeated dosing; premedicate with Lugol's solution 10 drops ORALLY three times daily starting at least 24 hours before administration, continue 1 to 2 weeks<\/li><li><b>Placental scan, Differential Diagnosis of Placenta Previa; Diagnosis:<\/b> placenta previa differential diagnosis, 3 to 5 microcuries IV; premedicate with Lugol's solution 10 drops ORALLY three times daily starting at least 24 hours before administration, continue 1 to 2 weeks<\/li><li><b>Plasma volume measurement; Diagnosis:<\/b> 0.185 to 1.85 megabecquerels (5 to 50 microcuries) IV; MAX 200 microcuries weekly for repeated dosing; premedicate with Lugol's solution 10 drops ORALLY three times daily starting at least 24 hours before administration, continue 1 to 2 weeks<\/li><li><b>Radionuclide localization of tumor, Cerebral Neoplasms:<\/b> 5 microcuries\/kg IV administered six hours before the initial examination; premedicate with Lugol's solution 10 drops ORALLY three times daily starting at least 24 hours before administration, continue 1 to 2 weeks<\/li><li><b>Radionuclide study, circulation time, Determination of cardiac and pulmonary circulation time; Diagnosis:<\/b> 75 to 130 microcuries IV; MAX 200 microcuries weekly for repeated dosing; premedicate with Lugol's solution 10 drops ORALLY three times daily starting at least 24 hours before administration, continue 1 to 2 weeks<\/li><li><b>Radionuclide study, protein kinetics, Protein Turnover; Diagnosis:<\/b> 10 to 150 microcuries IV; MAX 200 microcuries weekly for repeated dosing; premedicate with Lugol's solution 10 drops ORALLY three times daily starting at least 24 hours before administration, continue 1 to 2 weeks<\/li><li><b>Radionuclide study of heart, Heart and Great Vessel Delineation; Diagnosis:<\/b> 5 microcuries\/kg IV; premedicate with Lugol's solution 10 drops ORALLY three times daily starting at least 24 hours before administration, continue 1 to 2 weeks<\/li><\/ul>"},"1":{"id":"925314-s-1-5","title":"Pediatric Dosing","mono":"the safety and efficacy of iodinated I-131 albumin have not been established in children "},"3":{"id":"925314-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Blood volume estimation; Diagnosis<\/li><li>Isotope study of blood volume, Determination of cardiac and pulmonary blood volume; Diagnosis<\/li><li>Measurement of cardiac output; Diagnosis<\/li><li>Placental scan, Differential Diagnosis of Placenta Previa; Diagnosis<\/li><li>Plasma volume measurement; Diagnosis<\/li><li>Radionuclide localization of tumor, Cerebral Neoplasms<\/li><li>Radionuclide study, circulation time, Determination of cardiac and pulmonary circulation time; Diagnosis<\/li><li>Radionuclide study, protein kinetics, Protein Turnover; Diagnosis<\/li><li>Radionuclide study of heart, Heart and Great Vessel Delineation; Diagnosis<\/li><\/ul>"}}},"3":{"id":"925314-s-3","title":"Contraindications\/Warnings","sub":[{"id":"925314-s-3-9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"925314-s-3-10","title":"Precautions","mono":"<ul><li>radiopharmaceutical; handle with care and use safety measures to reduce radiation exposure to personnel and patient<\/li><li>cisternography use; reported cases of hyperpyrexia and aseptic chemical meningeal irritation; drug not approved for this indication<\/li><li>hypersensitivity; possible allergic reactions if additional dosing necessary<\/li><\/ul>"},{"id":"925314-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"925314-s-3-12","title":"Breast Feeding","mono":"<ul><li>AAP: Radioactive compounds that require temporary cessation of breastfeeding.<\/li><li>Micromedex: Infant risk cannot be ruled out.<\/li><\/ul>"}]},"5":{"id":"925314-s-5","title":"Adverse Effects","mono":"<b>Serious<\/b><ul><li><b>Neurologic:<\/b>Meningeal irritation<\/li><li><b>Other:<\/b>Hyperpyrexia<\/li><\/ul>"},"6":{"id":"925314-s-6","title":"Drug Name Info","sub":{"0":{"id":"925314-s-6-17","title":"US Trade Names","mono":"Volumex<br\/>"},"2":{"id":"925314-s-6-19","title":"Class","mono":"Diagnostic Agent<br\/>"},"3":{"id":"925314-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"925314-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"925314-s-7","title":"Mechanism Of Action","mono":"Iodinated I-131 albumin is a diagnostic radiopharmaceutical that acts by uniformly distributing into the intra- and extravascular spaces, thereby allowing for use in determination of total blood and plasma volumes, cardiac and pulmonary blood volumes and circulations, cardiac output, protein turnover studies, heart and great vessel delineation, localization of the placenta, and localization of cerebral neoplasms.<br\/>"},"8":{"id":"925314-s-8","title":"Pharmacokinetics","sub":{"3":{"id":"925314-s-8-26","title":"Excretion","mono":"<ul><li>Renal: significant urinary excretion<\/li><li>Feces: approximately 2%<\/li><\/ul>"},"4":{"id":"925314-s-8-27","title":"Elimination Half Life","mono":"normal subjects, approximately 14 days <br\/>"}}},"9":{"id":"925314-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>use proper procedures for handling and disposal of radiopharmaceuticals<br\/><\/li><li><b>Intravenous<\/b><br\/><ul><li>(blood and plasma volume determination) remove an aliquot identical in volume to dose administered to patient<\/li><li>(blood and plasma volume determination) prepare reference solution using normal saline as a diluent; recommended dilution 1:4000<\/li><li>(blood and plasma volume determination) determine radioactivity of reference solution<\/li><li>(blood and plasma volume determination) inject dose into large vein in arm; measure residual radioactivity in both syringe and needle<\/li><li>(blood and plasma volume determination) withdraw blood sample at 5 and 15 minutes from other arm after injecting dose; use sterile heparinized syringe<\/li><li>(blood and plasma volume determination) take a known aliquot from each blood sample and determine radioconcentration; for plasma volume concentration, blood is centrifuged and red blood cells are removed<\/li><li>(blood and plasma volume determination) determine background blood radioconcentration if serial blood volume or blood plasma measurements are necessary<\/li><\/ul><\/li><\/ul>"},"10":{"id":"925314-s-10","title":"Monitoring","mono":"no specific monitoring has been determined<br\/>"},"11":{"id":"925314-s-11","title":"How Supplied","mono":"<b>Volumex<\/b><br\/>Intravenous Solution: 25 uCi\/ML<br\/>"},"13":{"id":"925314-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug is excreted in breast milk. Use formula-feedings in place of breastfeedings.<\/li><li>Advise women of childbearing potential that examinations, especially those elective in nature, are ideally performed during the first few days (approximately 10 days) following onset of menses.<\/li><\/ul>"}}}